S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Procter & Gamble (PG) NyQuil: Teenage Drug Of Choice

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Getting high on cold mediciation appears to have become the "hot" path to a good time. And, it’s inexpensive and unregulated. Procter & Gamble’s (PG) NyQuil is now being headlined in the press as the most fun you can get in a bottle.

According to The Substance Abuse and Mental Health Sevices Administration "about  3.1 million people in the United States aged 12 to 25 (5.3 percent of this age group) have used over-the-counter (non-prescription) cough and cold medicines to get high at least once in their lifetimes." That puts its ahead of reported use of methamphetamines and about even with LSD.

The latest recipe for taking NyQuil is a mix of vodka, Red Bull and the cold medicine called a Purple Monster. The New York Post writes that the recipes for these cocktails are available online.

If  Procter & Gamble management wants to prevent a cascade of litigation and tremendouse negative PR, it needs to insist that their NyQuil products only be sold with a perscrption.

Douglas A. McIntyre 

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Why Procter & Gamble Just Scored a Major Upgrade After the Market Panic
Jon C. Ogg |

Why Procter & Gamble Just Scored a Major Upgrade After the Market Panic

Independent research firm Argus raised its rating on Procter & Gamble to Buy from Hold. Its $122 target price represented…
Dividend Kings Face-Off: Johnson & Johnson (JNJ) Vs. Procter & Gamble (PG)
Vandita Jadeja |

Dividend Kings Face-Off: Johnson & Johnson (JNJ) Vs. Procter & Gamble (PG)

If you are someone who thinks investments should generate regular income, it is important to watch out for dividend stocks.…
Just How Safe Is Procter & Gamble Stock’s Dividend?
Trey Thoelcke |

Just How Safe Is Procter & Gamble Stock’s Dividend?

Here is an assessment of how safe Procter & Gamble’s dividend appears to be based on a variety of metrics.
Dividend King Procter & Gamble Just Paid Investors: Here’s How Much They Received
Trey Thoelcke |

Dividend King Procter & Gamble Just Paid Investors: Here’s How Much They Received

Procter & Gamble has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of…
Walgreens vs. CVS: How They Compare
Rob Hayek |

Walgreens vs. CVS: How They Compare

Between 2022 and 2024, CVS closed roughly 900 locations nationwide. The company has recently announced it will close an additional…
3 High Yield Dividend Paying Stocks Perfect For Passive Income
Vandita Jadeja |

3 High Yield Dividend Paying Stocks Perfect For Passive Income

Market volatility, tariff uncertainty, and rising living costs remind investors that earned income alone is fragile. A layoff or unexpected…
Dividend King P&G Just Paid Investors: Here’s How Much They Received
Trey Thoelcke |

Dividend King P&G Just Paid Investors: Here’s How Much They Received

Procter & Gamble has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of…
Dividend King P&G Just Paid Investors: Here’s How Much They Got
Trey Thoelcke |

Dividend King P&G Just Paid Investors: Here’s How Much They Got

Procter & Gamble has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of…
Companies Most Likely to Raise Dividends in 2026
Douglas A. McIntyre |

Companies Most Likely to Raise Dividends in 2026

These four companies have increased their dividends annually for decades. And they will mostly likely boost their payouts again in…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618